<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512053</url>
  </required_header>
  <id_info>
    <org_study_id>10060070</org_study_id>
    <nct_id>NCT04512053</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence</brief_title>
  <official_title>A Phase 2, Randomized, Placebo-controlled, Double-blind Study of TAS-303 in Female Patients With Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female&#xD;
      patients with stress urinary incontinence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to assess the efficacy of TAS-303 in female patients with&#xD;
      stress urinary incontinence (SUI) compared with placebo as measured by the percent change in&#xD;
      the average SUI episode frequency per 24 hours from baseline at week 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percent change in the average SUI episode frequency per 24 hours</measure>
    <time_frame>Baseline, week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The average urinary incontinence episode frequency per 24 hours</measure>
    <time_frame>Baseline, week 4, week 8, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The urinary incontinence volume measured in a 24-hour pad test</measure>
    <time_frame>Baseline, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the international Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)</measure>
    <time_frame>Baseline, week 4, week 8, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the Patient's Global Impressions of Improvement (PGI I) questionnaire.</measure>
    <time_frame>Baseline, week 4, week 8, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the incontinence quality of life instrument (I QOL) scores</measure>
    <time_frame>Baseline, week 4, week 8, week 12</time_frame>
    <description>The minimum score is 22 points and the maximum is 110 points. The higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the overactive bladder symptom score (OABSS)</measure>
    <time_frame>Baseline, week 4, week 8, week 12</time_frame>
    <description>The minimum score is 0 points and the maximum is 15 points. The higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and side effects</measure>
    <time_frame>Up to 13 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>TAS-303</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-303 18 mg/day</intervention_name>
    <description>Oral administration for 12 weeks, once daily</description>
    <arm_group_label>TAS-303</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration for 12 weeks, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Patient has symptoms of Stress Urinary Incontinence (SUI) for at least 12 weeks prior&#xD;
             to study entry&#xD;
&#xD;
          -  Urinary incontinence in the 1-hour pad weight test exceeds 2.0 g&#xD;
&#xD;
          -  The average number of SUI episodes is 1 or more per day&#xD;
&#xD;
          -  The average number of urge urinary incontinence (UUI) episodes is 0.43 or less per day&#xD;
&#xD;
          -  The number of &quot;SUI episodes&quot; exceeds the number of &quot;other episodes&quot;&#xD;
&#xD;
          -  The average number of urinary diurnal frequency is 10 or less per day and the average&#xD;
             number of nocturia frequency is 2 or less per day&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Patient has been diagnosed with mixed urinary incontinence (MUI) that is predominantly&#xD;
             UUI&#xD;
&#xD;
          -  Patient has treated medication or therapy for SUI within 14 days before prior to study&#xD;
             entry&#xD;
&#xD;
          -  Patient is considered to have SUI that would not be expected to improve unless treated&#xD;
             with surgical therapy&#xD;
&#xD;
          -  Patient had a history of surgical treatment for urinary incontinence (Trans-obturator&#xD;
             tape surgery, Tension-free vaginal tape surgery, etc.)&#xD;
&#xD;
          -  Patient has stage II or more of Pelvic Organ Prolapse (POP), or had a history of POP&#xD;
             repair surgery within 180 days before prior to study entry&#xD;
&#xD;
          -  Patient has a serious illness or medical condition&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taiho Pharmaceutical Co., Ltd.</last_name>
    <role>Study Director</role>
    <affiliation>Taiho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A site selected by Taiho Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A site selected by Taiho Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A site selected by Taiho Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A site selected by Taiho Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Incontinence</keyword>
  <keyword>Urinary Incontinence, Stress</keyword>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Taiho Group (Taiho) provides a platform for accepting researchers requests for sharing anonymized, patient-level, analyzable datasets from articles published in peer-reviewed journals about the primary results from Taiho-sponsored interventional clinical trials in patients in which the medicine and the indication has received marketing approval from regulatory authorities in the United States, the European Union, and/or Japan on or after January 15, 2018.&#xD;
Access to the clinical trial data is contingent upon approval of a proposed study protocol by an independent review panel and the execution of a data-sharing agreement with the researcher.&#xD;
See: https://www.taiho.co.jp/en/science/policy/clinical_trial_information_disclosure_policy/index.html</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

